Summary
Agilent Technologies, Inc. reported net revenue of $6.833 billion for the fiscal year ended October 31, 2023, a slight decrease compared to the prior year, primarily due to weaker demand in China and pressures on customer capital expenditures impacting the Life Sciences and Applied Markets segment. However, the Diagnostics and Genomics segment saw a slight increase, and the Agilent CrossLab services business demonstrated robust growth of 8%. The company incurred significant asset impairment charges of $270 million related to the exit of its Resolution Bioscience business, which impacted net income, though overall net income remained stable year-over-year at $1.240 billion. Agilent continued its focus on capital allocation, repurchasing $476 million of its stock under its 2023 repurchase program and paying $265 million in dividends. The company also announced a new restructuring plan in fiscal year 2023, involving a workforce reduction and facility consolidation, expected to yield $80 million in annual cost savings. Looking ahead, Agilent anticipates a challenging macroeconomic environment but remains optimistic about long-term growth opportunities across its key end markets.
Financial Highlights
57 data points| Revenue | $6.83B |
| Cost of Revenue | $3.37B |
| Gross Profit | $3.46B |
| R&D Expenses | $481.00M |
| SG&A Expenses | $1.63B |
| Operating Expenses | $5.48B |
| Operating Income | $1.35B |
| Interest Expense | $95.00M |
| Net Income | $1.24B |
| EPS (Basic) | $4.22 |
| EPS (Diluted) | $4.19 |
| Shares Outstanding (Basic) | 294.00M |
| Shares Outstanding (Diluted) | 296.00M |
Key Highlights
- 1Net revenue for fiscal year 2023 was $6.833 billion, a slight decrease from $6.848 billion in fiscal year 2022, impacted by foreign currency movements and weaker demand in certain markets.
- 2The company recorded a significant $270 million asset impairment charge related to the exit of its Resolution Bioscience business.
- 3Agilent CrossLab, the services segment, showed strong growth with an 8% increase in revenue year-over-year, reaching $1.568 billion.
- 4Net income for fiscal year 2023 was $1.240 billion, largely consistent with the $1.254 billion reported in fiscal year 2022.
- 5The company initiated a restructuring plan in fiscal year 2023, including a workforce reduction of approximately 400 employees, expecting $80 million in annual cost savings.
- 6Agilent continued its share repurchase program, buying back $476 million of stock, and paid $265 million in dividends, demonstrating commitment to shareholder returns.
- 7Investments in property, plant, and equipment were $298 million, with significant planned expansion for nucleic acid-based therapeutics production in Frederick, Colorado.